and also to nuclear DNA via its N-terminal CCP module pair (CCP1/2), tethering active IL-33 within necrotic cells, preventing its release, and forestalling initiation of type 2 allergic responses. Thus, HpARI employs a novel molecular strategy to suppress type 2 immunity in both infection and allergy.
In Brief
Osbourn et al identified HpARI, a protein secreted by a helminth parasite that is capable of suppressing allergic responses. HpARI binds to IL-33 (a critical inducer of allergy) and nuclear DNA, preventing the release of IL-33 from necrotic epithelial cells.
SUMMARY
Infection by helminth parasites is associated with amelioration of allergic reactivity, but mechanistic insights into this association are lacking. Products secreted by the mouse parasite Heligmosomoides polygyrus suppress type 2 (allergic) immune responses through interference in the interleukin-33 (IL-33) pathway. Here, we identified H. polygyrus Alarmin Release Inhibitor (HpARI), an IL-33-suppressive 26-kDa protein, containing three predicted complement control protein (CCP) modules. In vivo, recombinant HpARI abrogated IL-33, group 2 innate lymphoid cell (ILC2) and eosinophilic responses to Alternaria allergen administration, and diminished eosinophilic responses to Nippostrongylus brasiliensis, increasing parasite burden. HpARI bound directly to both mouse and human IL-33 (in the cytokine's activated state) and also to nuclear DNA via its N-terminal CCP module pair (CCP1/2), tethering active IL-33 within necrotic cells, preventing its release, and forestalling initiation of type 2 allergic responses. Thus, HpARI employs a novel molecular strategy to suppress type 2 immunity in both infection and allergy.
INTRODUCTION
Infection with helminth parasites negatively correlates with prevalence of allergic disease, and parasitic infection is associated with immunosuppression (Maizels and McSorley, 2016) . Many researchers, ourselves included, have demonstrated that helminths release immunomodulatory proteins to control antiparasite immune responses and maintain their persistence in the host (Maizels and McSorley, 2016) . We previously showed that the excretory-secretory products of the mouse intestinal parasite Heligmosomoides polygyrus (HES) suppress allergic responses in mouse models of asthma (Buck et al., 2014; McSorley et al., 2015; McSorley et al., 2014; McSorley et al., 2012) . HES administration blocks the interleukin-33 (IL-33) response to inhaled Alternaria (fungal) allergen leading to reduced type 2 innate lymphoid cell (ILC2) responses and abrogating lung pathology.
IL33 and its receptor (IL1RL1) are both among the 10 genes most strongly linked to allergic sensitization (Bønnelykke et al., 2013) and asthma (Bønnelykke et al., 2014; Moffatt et al., 2010) in genome-wide association studies. IL-33 concentration is increased in the lungs of severe asthmatics (Castanhinha et al., 2015; Saglani et al., 2013) , correlating negatively with lung function (Christianson et al., 2015) . Respiratory viral infections are implicated in both initiation and exacerbation of asthma, an effect that is also associated with IL-33 release (Jackson et al., 2014; Saravia et al., 2015) .
The IL-33 receptor (ST2, IL1RL1, IL-33R) is expressed by a wide range of cells, notably T cells, macrophages, endothelial cells, epithelial cells, and ILC2 . Through these interactions, IL-33 drives type 2 immune responses in a range of diseases including asthma, atopic dermatitis, food allergy, COPD, eosinophilic inflammatory bowel disease, eosinophilic esophagitis, and age-related macular degeneration (De Salvo et al., 2016; Liew et al., 2016; Simon et al., 2015; Tordesillas et al., 2014) . IL-33 is a member of the IL-1 family of cytokines. It is stored preformed in the nucleus bound to heterochromatin, and its dominant function is as an alarmin cytokine. Active IL-33 is released from the nucleus under conditions of necrosis, while during apoptosis active caspases cleave IL-33 within its receptor-binding domain, abolishing activity (Lefranç ais . Although the full-length, 30 kDa form of IL-33 is functional, the activity of IL-33 is increased 10-fold through cleavage between the DNA-binding and receptor-binding domains by proteases such as calpain-2 (Hristova et al., 2016) , neutrophil elastase, cathepsin G (Lefranç ais et al., 2012), and mast cell tryptase (Lefranç ais et al., 2014) releasing 18-21 kDa mature forms. Active IL-33 is released in a reduced form, which under physiological conditions rapidly oxidizes, forming new disulfide bonds and changing conformation, rendering it unable to bind to the IL-33R beyond a short temporal and spatial range (Cohen et al., 2015) .
Here, we identified H. polygyrus Alarmin Release Inhibitor (HpARI), a HES-derived recombinant protein that can replicate the IL-33-suppressive effects of total HES. HpARI bound directly to active murine or human IL-33 and nuclear DNA. This dual binding blocked the interaction of IL-33 with its receptor, and tethered IL-33 within necrotic cells, preventing its release, and blocking allergic response initiation. Thus, HpARI prevents initiation of parasite-toxic IL-33-mediated type 2 immune responses and suppresses the development of allergic airway inflammation.
RESULTS
In Vitro Suppression of IL-33 by HES Previous studies established that HES ablates detectable IL-33 in the bronchoalveolar milieu after Alternaria allergen administration, suppressing downstream allergic responses . To further investigate the IL-33-suppressive activity of HES, we developed an in vitro assay for IL-33 release: a single cell suspension of naïve total murine lung cells cultured for 1 hr in the presence of Alternaria allergen and HES. In this assay, HES markedly reduced the amount of IL-33 in culture supernatants, as detected by ELISA ( Figure 1A) .
IL-33 is released from lung epithelial cells under conditions of necrosis, whereas activated caspases cleave IL-33 within the IL-1-like cytokine domain, inactivating IL-33 under conditions of apoptosis . We therefore hypothesized that HES could be activating caspase and/or apoptosis pathways. Propidium iodide and annexin V staining showed that cells incubated with Alternaria allergen were highly necrotic and that this was unaffected by the presence of HES ( Figure 1B) . Necrosis induced by freeze-thaw treatment of lung cells also resulted in substantial IL-33 release, which again was abrogated by treatment of cells with HES immediately prior to freezing ( Figure 1C ). Therefore we conclude that HES suppression of IL-33 does not depend on activation of the apoptosis pathway, but instead acts on pre-formed IL-33 released from necrotic cells.
Identification and Characterization of HpARI Protein
A process of fractionation, screening, and proteomic analysis of HES was used to identify candidate IL-33-suppressive proteins. Gel filtration and anion exchange FPLC were used to fractionate HES by size and charge, respectively. IL-33 suppressive activity peaked around size fraction 11 ( Figure 2A ) and charge fraction 25 ( Figure 2B ). Each size and charge fraction was subjected to trypsin digestion followed by liquid chromatography-electrospray tandem mass spectrometry (LC-MS/MS), and the exponentially modified protein abundance index (emPAI) value for each HES protein in every fraction was calculated, and compared to the profile of IL-33 suppression.
By size fractionation, 220 proteins were found with emPAI values which peaked around size fraction 11 (peak value in fractions 10-12), while 371 proteins were found with emPAIs which peaked around charge fraction 25 (peak value in fractions 23-27), 54 of which were shared between the two fractionation techniques. Proteins were prioritized wherein more than one peptide was detected in size fraction 11 and charge fraction 25, resulting in a short-list of 25 candidate proteins (Table S1 ).
The emPAI values for each of these 25 candidates for all size and charge fractions was then manually compared to the IL-33 suppression profile ( Figure S1A ), and 4 candidates were selected for initial screening ( Figure S1B ).
The 4 candidate IL-33 suppressive genes were transfected into HEK293T cells for expression, and screened for suppression Figure 2E and Figure S2A ).
The three predicted HpARI CCP module sequences were modelled individually based upon their top ranked CCP module template structures. Each CCP module 3-D model is characterized by a b-sheet framework, held together by two disulfide bridges. Other key structural features such as the location of the buried Trp/Leu, hypervariable loop, and potential N-glycosylation sites are indicated along with the relative positions of the novel insertions in CCP2 and CCP3, which could not be modelled on conventional experimentally determined CCP module structures ( Figure 2F ).
In Vitro and In Vivo IL-33 Suppression by HpARI Recombinant mature 6-His and Myc-tagged HpARI protein was purified by metal chelating chromatography ( Figure S2B ), and tested for IL-33 suppression in vitro. HpARI was active at <10 ng/ml, while HES required an approximately 50-fold higher concentration for a similar effect ( Figure 3A ). The IL-33-suppressive activity of HpARI in response to Alternaria culture or freezethaw was ablated on heat-treatment, as with HES (Figures S3A and S3B) .
HpARI also effectively suppressed IL-33 detected in bronchoalveolar lavage (BAL) fluids in response to Alternaria allergen in vivo ( Figure 3B ). Again this effect replicated that of HES and suppression was ablated when HpARI was proteolytically cleaved and heat-treated, ruling out a role for non-protein contaminants. In addition, the IL-33-suppressive effects of HpARI could pre-condition airway tissues, substantially reducing the IL-33 response to Alternaria allergen 24 hr later, with a degree of protection in some animals even after 72 hr ( Figure 3C ). Thus, HpARI appears to be a critical IL-33-suppressive factor in HES.
Suppression of In Vivo Type 2 Responses by HpARI
Alternaria exposure induces a rapid T cell-independent eosinophilia within 24 hr of administration. This response is driven by ILC2 cytokine release, and is critically dependent on IL-33 (Bartemes et al., 2012) . Recombinant HpARI co-administration with Alternaria allergen abrogated BAL eosinophilia ( Figure 3D ) and lung ILC2 IL-5 ( Figure 3E ) and IL-13 production ( Figure 3F ), 24 hr later, again replicating the effects observed with total HES. IL-13-eGFP reporter mice were used to assess ILC2 cytokine responses in the absence of PMA and Ionomycin stimulation, confirming profound suppression of IL-13 reporter expression in ICOS + CD90.2 + IL-33R
HpARI was administered in a T cell-dependent model of asthma, in which OVA protein is first co-administered with Alternaria, and antigen-specific type 2 responses recalled 2 weeks later by challenge with OVA protein alone . Again HpARI replicated the suppressive effects of HES on BAL eosinophilia and lung ILC2 responses ( Figures 4A-4C ). Furthermore, this suppression led to significantly abrogated lung resistance and compliance at challenge (Figures 4D and 4E) , as well as reduced inflammation and mucus production assessed by histological staining ( Figure 4F-4H) .
Finally, the role of HpARI in parasite infections was addressed using Nippostrongylus brasiliensis infection, a parasite which (unlike H. polygyrus) migrates through the lung and leads to early IL-33-dependent type 2 responses (Hung et al., 2013) . Similarly to the phenotype seen in an IL-33-deficient mouse, HpARI administration did not affect worm burden at early timepoints, but increased numbers of adult parasites found in the intestinal lumen at day 6 ( Figures 4I and 4J ). This suppression of parasite rejection was associated with reduced BAL eosinophilia, reaching significance at day 6 ( Figure 4K ). Thus, HpARI abrogates parasiteor allergen-induced IL-33-dependent type 2 immune responses, abrogating parasite ejection and suppressing allergic pathology.
HpARI Binding to IL-33
We hypothesized that HpARI could act by binding directly to IL-33. To investigate this, we incubated Myc-tagged HpARI with murine lung cell homogenates, and immunoprecipitated with anti-c-Myc antibody bound to protein G-coated beads. HpARI immunoprecipitated a clear band at 18 kDa in Myctagged complexes eluted from anti-c-Myc-coated, but not isotype control-coated beads, as revealed by anti-IL-33 western blotting ( Figure 5A ). Unbound material (supernatants from coimmunoprecipitation) showed undetectable or very faint bands for IL-33 under these conditions, reflecting the manner in which immunoprecipitation concentrates ligand sufficiently for detection. No band could be detected for full-length IL-33 (30 kDa) in these experiments (data not shown). Despite human and murine IL-33 sharing only 52% amino acid identity, we found that human IL-33 also co-immunoprecipitates with HpARI after incubation with human lung homogenates, seen as an 18 kDa band corresponding to mature human IL-33 (Figure 5B) . In this case, unbound human IL-33 could be detected in supernatants from co-immunoprecipitation or control conditions, also at 18 kDa.
To biochemically characterize the binding of human and mouse IL-33 with HpARI, we assessed the interactions between these proteins by surface plasmon resonance (SPR) ( Figures 5C  and 5D ). The equilibrium dissociation constant (KD) of HpARI for murine IL-33 is 0.56 ± 0.1 nM, and 260 ± 13 nM for human IL-33.
Oxidation of IL-33
Recently, it was shown that IL-33 is released in an active reduced form, which is quickly oxidized (<4 hr after release) and inactivated under physiological conditions (Cohen et al., 2015) .
Commercially-available IL-33 ELISA kits do not differentiate between the reduced and oxidized forms. Therefore we decided to investigate whether HpARI preferentially bound to reduced or oxidized IL-33.
To attain a source of oxidized and reduced IL-33, we subjected lung cells to freeze and thaw-mediated necrosis, harvested IL-33-containing supernatants immediately postthaw, and incubated these at 37 C for 1-4 hr to oxidize IL-33 (Cohen et al., 2015) . When HpARI was added to supernatants directly post-thaw, or up to 2 hr later, it was able to significantly reduce the IL-33 signal as measured by ELISA, whereas by 4 hr post-thaw, no effect of HpARI could be seen ( Figure 5E and Figure S4A ). Therefore we hypothesized that HpARI binds only to active (reduced) IL-33.
HpARI co-immunoprecipitation experiments were then repeated with either untreated recombinant murine IL-33 (rmIL-33) or rmIL-33 which had been oxidized by incubation for 24 hr at 37 C in tissue culture medium. Eluted complexes were run on non-reducing SDS-PAGE gels to distinguish reduced and oxidized IL-33 by their differential migration under non-reducing conditions, the more compact oxidized form migrating more rapidly (Cohen et al., 2015) . A strong bias for binding of HpARI to the reduced form could be seen, with unbound supernatants containing the oxidized form, while no unbound reduced IL-33 could be detected ( Figure 5F ). Co-immunoprecipitation was repeated with recombinant human IL-33 (rhIL-33), either untreated or oxidized under the same conditions as applied to murine IL-33. Similarly to murine IL-33, rhIL-33 could only be bound by HpARI in its reduced, active form, with oxidation of IL-33 abolishing its ability to be co-precipitated ( Figure 5G) .
IL-13+ % of
Finally, we ensured that the binding of HpARI is specific to IL-33, by binding studies with the closely-related IL-1 family cytokine IL-1a. No binding of HpARI to IL-1a could be detected, either by co-immunoprecipitation ( Figure 5H ) or by SPR (Figure S4B) . Thus, HpARI specifically and with high affinity, binds to the active, reduced form of IL-33.
HpARI Prevents Binding of Active IL-33 to the IL-33 Receptor To investigate whether HpARI binding IL-33 consequently affected downstream responses to IL-33, we investigated the binding of IL-33 to its receptor ST2. Recombinant mIL-33 was incubated alone or with HpARI, then immunoprecipitation was carried out using an ST2-Fc fusion protein bound to protein G-coated magnetic beads. The presence of HpARI completely blocked immunoprecipitation of rmIL-33 by ST2-Fc ( Figure 6A ), implying that HpARI prevents IL-33 from binding to its receptor. Furthermore, when rmIL-33 was administered intranasally to mice, IL-33-mediated ILC2 activation (measured by IL-5 and IL-13 production) was effectively ablated by HpARI co-administration ( Figures 6B and 6C ). Thus HpARI, through binding to IL-33, can prevent the activation of ILC2s through ST2 ligation.
HpARI Inhibits Release of IL-33
As HpARI directly binds IL-33, it could also interfere with detection of the cytokine by ELISA through masking epitopes bound by assay antibodies. This could affect our early screening results, (Figures 1, 2 , and 3) as these are largely dependent on ELISA to measure concentrations of IL-33. To investigate the possibility of undetectable HpARI-bound IL-33 in BAL supernatants, we measured IL-33 by both ELISA and western blot, as the latter reduces, denatures and dissociates protein complexes. Mice were treated with Alternaria allergen and BAL taken 15 min later (at which timepoint the majority of IL-33 released is active and reduced [Cohen et al., 2015] ), HpARI coadministration ablated the IL-33 signal by ELISA ( Figure 6D ), and significantly inhibited (but did not ablate) the IL-33 signal by western blot ( Figure 6E ), implying that although HpARI binding interferes with IL-33 detection by ELISA, IL-33 release is indeed diminished with HpARI administration. In contrast, HpARI could not affect the release of HMGB1, another nuclear-localised alarmin cytokine released on necrosis, (Figure S4C ), demonstrating that the effects of HpARI are specific to IL-33.
To translate these results to human biology, we cultured human lung explants for 1 hr with HpARI, a system and timepoint in which lung explants spontaneously release reduced (active) human IL-33 (Cohen et al., 2015) . Similarly to the murine system, a reduction in IL-33 signal was seen with HpARI coadministration, as measured by both ELISA and western blot ( Figures 6F and 6G) . Furthermore, HpARI was administered with Alternaria to human IL-33 transgenic mice (Cohen et al., 2015) , where it again suppressed human IL-33 release into the BAL (Figures 6H and 6I) . Thus, HpARI reduces the release of both mouse and human IL-33.
Immunofluorescent Localization of HpARI
To further investigate the mechanism of action of HpARI, we utilized the CMT-64 mouse lung epithelial carcinoma cell line, which we found stores high amounts of IL-33 in the nucleus ( Figure S5A ). Similarly to lung cells cultured in vitro, IL-33 is released from freeze-thawed CMT-64 cells, and this response is suppressed by HpARI ( Figure S5B ). We then produced an HpARI_mCherry fusion protein, allowing fluorescent localization of HpARI binding, while retaining IL-33-suppressive activity ( Figure S5C ).
Although we found no HpARI_mCherry staining of live CMT-64 cells, binding was evident in freeze-thaw treated necrotic cells ( Figure 7A ), where it bound in the nucleus ( Figure 7B) . Surprisingly, we found HpARI_mCherry binds the nucleus independently of IL-33 expression, as similar staining could be seen in HEK293 cells ( Figure 7C ), from which no IL-33 could be detected (data not shown). As binding of HpARI in the nucleus of CMT-64 or HEK293 cells was ablated by addition of DNAse I ( Figure 7C ), we hypothesized that HpARI binds directly to DNA in the nucleus of necrotic epithelial cells.
In vivo, DNAse co-administration with Alternaria allergen abrogated HpARI suppression of IL-33 as measured by western blot, but not by ELISA, in the latter case presumably due to steric hindrance of ELISA antibodies on released HpARIbound IL-33 ( Figures 7D and 7E) . We conclude that dual binding of DNA and IL-33 by HpARI results in retention of IL-33 within the necrotic cell nucleus, conferring a tethering function on HpARI in addition to its ability to block IL-33 in the fluid phase.
Binding of DNA by HpARI was confirmed using a gel shift assay, in which addition of HpARI retarded the migration of linear plasmid DNA through an agarose gel in a concentration-dependent manner ( Figure 7F ), and by immunoprecipitation of plasmid DNA by HpARI ( Figure S5D ). We hypothesised that HpARI could bind DNA through electrostatic interactions, as shown for other CCP module-containing proteins (Sjö berg et al., 2007; Trouw et al., 2005) . When the isoelectric point (pI) of each of the three CCP domains of HpARI were calculated, CCP2 and CCP3 were found to be relatively acidic (pI 6.32 and 5.34 respectively), while CCP1 was strongly basic (pI 9.79). Indeed, an electrostatic surface representation of our 3-D model of CCP1 (Figure S5E ), reveals clusters of solvent-exposed positively charged residues that could serve as a binding site for oppositely-charged (acidic) DNA. We produced truncated versions of HpARI, either encod- ing CCP1/2 or CCP2/3. As predicted, we found that only the CCP1/2 truncation caused a shift in DNA migration (Figure 7F) , supporting a role for CCP1 in binding to DNA.
In vivo, only the CCP1/2 HpARI truncation could inhibit the release of IL-33 as measured by western blot, while CCP2/3 actually increased total quantities of IL-33 detected in the BAL ( Figure 7G ). Both constructs suppressed IL-33 detection by ELISA ( Figure 7H ), indicating they could both bind IL-33 and inhibit binding of ELISA antibodies. Therefore we propose that CCP2/3 does not inhibit IL-33 release but instead binds it in solution, prevent it from being degraded or taken up via its receptor. This data supports a model by which HpARI binds to IL-33 through its CCP2 domain, and to DNA through its CCP1 domain, tethering IL-33 within the necrotic cell nucleus.
DISCUSSION
IL-33 has emerged as a critical initiator of allergic responses in diseases such as asthma, sparking an array of type 2 reactions in innate lymphoid cells, eosinophils, macrophages, and T cells (Liew et al., 2016) . Through screening of the secreted products of a helminth parasite we identified HpARI, a CCP module-containing protein that inhibits IL-33 release. Recombinant HpARI is non-cell permeable, and can only gain access to the nucleus of necrotic cells, where it binds directly to IL-33 and nuclear DNA, tethering IL-33 within necrotic cells and preventing binding to the IL-33R, thereby suppressing ILC2 responses and eosinophilia in the lung after Alternaria administration.
The primary mechanistic effect of HpARI is to bind IL-33: remarkably, this extends from murine to human IL-33. Although the affinity of HpARI for human IL-33 is lower than that of mouse IL-33, this binding is sufficient to prevent human IL-33 release, with a reduced IL-33 signal in human lung explant supernatants when cultured with HpARI, and reduced human IL-33 release in the lungs of human IL-33 transgenic mice. In the mouse, HpARI proved to be highly suppressive in vivo, recapitulating and exceeding the effects of total parasite secretions (HES), and able to inhibit IL-33 release even when administered 24 hr prior to allergen challenge.
Although it is clear that IL-33 is released at high levels during tissue injury and necrosis, it is presently unclear how IL-33 is secreted during homeostasis (Liew et al., 2016) . We showed that HpARI was not able to penetrate intact cells thus, in the absence of cell membrane damage, HpARI would be unable to mediate the nuclear retention of IL-33. HpARI's unique mechanism of action and specificity provide an interesting tool to investigate the role of IL-33 as an alarmin-preventing the release of IL-33 from necrotic cells while leaving other responses (necrosis, HMGB1 or IL-1a release) unaffected. Recently, IL-33 production and release by activated mast cells in response to extracellular ATP release was demonstrated in H. polygyrus infection (Shimokawa et al., 2017) , and extracellular ATP has previously been shown to induce IL-33 release in response to Alternaria administration (Kouzaki et al., 2011) . These findings might explain the lack of total ablation of IL-33 release with HpARI administration, as some cytokine might be actively secreted by live mast cells, against which the tethering function of HpARI would be inactive, without exposed DNA in a necrotic, lysed cell. In this context, the role of H. polygyrus secreted apyrases )-enzymes which degrade extracellular ATP-might have a further role.
Binding to nuclear DNA allows HpARI to hold active IL-33 within the necrotic cell, and ablates allergic sensitization. Although the affinity for DNA was not determined in this study, evidence from gel shift and co-immunoprecipitation assays, as well as ablation of necrotic nuclear localization and IL-33 tethering function on DNAse treatment, strongly supports binding of HpARI to DNA. Truncated HpARI lacking CCP1 has no activity in the gel shift assay and lacks IL-33 tethering functionality, and molecular modeling of CCP1 revealed 2 exposed basic patches as putative DNA binding sites. Of note, the mammalian CCP domain-containing proteins C4b-binding protein (C4BP) (Trouw et al., 2005) and complement factor H (Leffler et al., 2010) , also bind DNA through basic CCP modules. The importance of IL-33 localization to the nucleus has been shown in transgenic mice lacking the nuclear localization domain of IL-33, which develop lethal eosinophil-dominant multi-organ inflammation (Bessa et al., 2014) , and in human endothelial cells, where extracellular IL-33 leads to inflammatory responses, while nuclear IL-33 does not (Gautier et al., 2016) .
Three predicted CCP modules span the length of mature HpARI. CCP module-containing proteins are present in different phyla including chordates and nematodes, with notable expansion and diversification in parasitic species such as H. polygyrus . The functions of CCP modules are diverse, underlining the versatility of this structural scaffold that has evolved to serve many purposes (Kirkitadze and Barlow, 2001; . Of note, no non-host CCP module-containing protein has previously been shown to have immunomodulatory function outside of the complement system, and hence the co-option of this module by a parasite to block a mammalian immunological pathway is remarkable.
The suppression of the IL-33 pathway by H. polygyrus at the level of the IL-33 cytokine (mediated by HpARI) and the IL-33 receptor (mediated by secreted exosomes [Buck et al., 2014]) indicates that this pathway might be critical to persistence of the parasite. Indeed administration of exogenous IL-33 induces expulsion of H. polygyrus , while IL-33R-deficient mice are slow to expel this parasite even when immunized with a vaccine that induces sterile immunity in wild-type mice (Coakley et al., 2017) . Similarly, in many helminth infections IL-33 administration can drive immunity, while deficiency of IL-33 or the IL-33 receptor leads to increased parasite load (Maizels and McSorley, 2016) . Hence, the ability of H. polygyrus to pre-empt the IL-33 alarmin system is likely to be a pivotal evolutionary adaptation to allow establishment in the mammalian host.
HpARI administration suppressed the eosinophilic response to N. brasiliensis infection, leading to reduced ejection of adult parasites from the intestinal lumen, similarly to the phenotype seen in IL-33-deficient animals (Hung et al., 2013) . Thus HpARI is capable of suppressing early innate anti-parasite immunity, a role we hypothesize it to play in the early stages of H. polygyrus infection where IL-33 is critical for resistance (Coakley et al., 2017) .
During an H. polygyrus infection, larvae penetrate the gut wall, undergo two molts in the subserosal membrane, and emerge back into the lumen of the gut as adults . As the parasite penetrates the intestinal wall, it damages epithelial cells which could result in the release of pre-formed IL-33 and induction of a parasite-toxic type 2 immune response. HpARI is secreted by the parasite larvae and adult and so is well positioned to ablate this IL-33 response.
Recently, IL-33 was implicated in activation of intestinal Foxp3 + regulatory T (Treg) cells (Schiering et al., 2014) raising the possibility that HpARI could interfere with Treg cell-mediated suppression. However, in mouse models of asthma, IL-33 signaling to IL-33R + Foxp3 + Treg cells results in their expression of Th2 cytokines, and abrogation of suppressive ability (Chen et al., 2017) . Thus, in asthmatic responses at least, IL-33 appears to have an inflammatory, rather than suppressive effect.
In conclusion, we have identified a CCP module-containing protein with the unique ability to selectively bind to IL-33 and DNA within necrotic epithelial cells. This activity potently suppresses the release and the biological activity of IL-33, resulting in suppression of type 2 responses to allergen challenge. IL-33 is a critical mediator in allergic disease and an important clinical target. HpARI could be a potent agent for prevention of IL-33-mediated pathology, as well as a new tool for manipulation of IL-33 release, leading to better understanding of the IL-33 pathway.
STAR+METHODS
Detailed methods are provided in the online version of this paper and include the following: 
METHOD DETAILS
Parasite lifecycles, Infection, and HES Preparation The life cycle of H. polygyrus bakeri was maintained, and HES products prepared, as previously described (Johnston et al., 2015) . The life cycle of N. brasiliensis was maintained in Sprague-Dawley rats as previously described (Lawrence et al., 1996) , and infective L3 larvae were prepared from 1-3 week rat fecal cultures. BALB/c mice were subcutaneously infected with 500 L3 N. brasiliensis larvae. At day 3 post-infection, larvae were counted in the bronchoalveolar lavage and in lung tissue, by dicing lungs and placing them in a cheese-cloth bag in a 50 ml tube containing PBS at 37 C for at least 3 h. Day 3 lung counts reflect a sum of the BAL and lung larval counts for each animal. At day 6 intestinal worms were recovered from intestinal tissue using an adapted Baermann apparatus.
Reagents
Alternaria alternata extract (Greer XPM1D3A25) was resuspended in PBS, filter sterilized and concentration assessed by BCA assay (Pierce). CMT-64 cells (ECACC 10032301) and HEK293T cells (ATCC CRL-3216) were maintained by serial passage in DMEM medium containing 10% fetal bovine serum, 2 mM L-glutamine and 1 mg ml -1 penicillin/streptomycin. Human and murine IL-33 and murine IL-1a were purchased from BioLegend.
In Vitro IL-33 Release Assay HES, candidate proteins or HpARI were cultured with total murine lung cells prepared by Liberase/DNAse digestion of naïve mouse lungs or CMT-64 cells for 1 h at 37 C, 5% CO 2 , with Alternaria allergen (200 mg ml -1 ), or were frozen on dry ice, and thawed at 37 C.
Preparation of Murine Lung Single Cell Suspension
Single-cell suspensions of naïve murine lung tissue were prepared by digesting in 2 U ml -1 liberase TL (Roche, Burgess Hill, UK) and 80 U ml -1 DNase (Life Technologies, Paisley, UK) at 37 C with agitation for 35 min. Digested tissue was macerated through a 70 mm cell strainer (BD Biosciences), treated with red blood cells lysis buffer (Sigma), and live cells counted on a haemocytometer, excluding dead cells by trypan blue staining.
Cytokine Measurement R&D Systems Duoset kits were used to measure human and murine IL-33 by ELISA, while western blotting was carried out using polyclonal goat anti-mouse IL-33, goat anti-human IL-33 or goat anti-mouse IL-1a (R&D Systems) with a rabbit anti-goat IgG HRP secondary antibody (Thermo Fisher), and detected using WesternSure Premium reagent (Licor).
